Business

Galecto Biotech announced that it raised €79 million in a series C financing round that will be used to fund a Phase 2/3 study of its TD139, an inhaled galectin-3 inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF). New investors included Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Maverick Ventures, Seventure Partners, and … [Read more...] about Galecto Biotech raises €79 million for Phase 2/3 study of its inhaled galectin-3 inhibitor

VistaGen Therapeutics said that it has exercised an option to acquire an exclusive worldwide license for Pherin Pharmaceutical's PH10 intranasal steroid, which is in Phase 2 development for the treatment of major depressive disorder (MDD). According to the company, a Phase 2a study of PH10 conducted by MIchael Liebowitz of Columbia University demonstrated significant … [Read more...] about VistaGen acquires second Pherin nasal spray

Milestone Pharmaceuticals said that it has completed an $80 million financing round led by RTW Investments, a new investor. Proceeds will be used for Phase 3 development of its intranasal etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT), which recently got underway, for certain commercial activities prior to an anticipated launch of the … [Read more...] about Milestone Pharmaceuticals raises $80 million for Phase 3 development of intranasal etripamil

Canadian cannabis grower FSD Pharma has signed a letter of intent to acquire Therapix Biosciences for $48 million, the company said. Therapix has licensed intranasal cannabinoid delivery technology from Yissum Research Development Company, which is the technology transfer company for Hebrew University, and cannabinoid researcher Raphael Mechoulam of Hebrew University … [Read more...] about FSD Pharma to acquire Therapix Biosciences

A joint venture of Cipla, Cooper Pharma, and the Pharmaceutical Institute has constructed a new metered dose inhaler manufacturing plant in a suburb of Rabat, Morocco that opened officially as of October 14, 2018. The $6.4 million plant is situated on a 4,000 sq m site and has a capacity of 1.5 million MDIs per year. Eleven of the 15 different SKUs of MDIs … [Read more...] about New MDI manufacturing facility opened in Morocco

Seurat Therapeutics, a start-up biotech based at the University of Chicago, has received a grant of almost $510,000 from the National Institute of Neurological Disorders and Stroke for development of its intranasal IGF-1 for the treatment and prevention of migraines, the company said. In 2016, Seurat, then called Cephalgia, received $250,000 from the University of … [Read more...] about Seurat Therapeutics gets $510,000 grant for development of intranasal migraine therapy

According to Medical Developments International (MVP), Daiichi Sankyo will pay up to $32.5 million for the rights to distribute MVP's Penthrox methoxyflurane inhaler in China, Vietnam, and Thailand. The deal includes $15 million up front plus sales milestones. MVP will pay up to $10 million toward acquiring marketing approval in China, will own the drug import … [Read more...] about Daiichi Sankyo to distribute Penthrox methoxyflurane inhaler in China

United Therapeutics will pay Samumed $10 million up front and up to $340 million in milestones, plus royalties, for North American rights to Samumed's SM04646, a Wnt signaling pathway inhibitor that in in Phase 1 development for the treatment of idiopathic pulmonary fibrosis (IPF). A United Therapeutics subsidiary, Lung Biotechnology PBC, will take over and pay … [Read more...] about United Therapeutics licenses inhaled IPF drug from Samumed

DPI developer TFF Pharmaceuticals has received a communication from the European Patent Office (EPO) in regards to its patent application No. 08771657.7 “Formation of Stable Submicron Peptide or Protein Particles by Thin Film Freezing,” giving notice of the EPO's intention to grant a patent. TFF Pharmaceuticals CEO Glenn Mattes commented, “We are very pleased to … [Read more...] about TFF Pharmaceuticals gets European patent for particle technology